Revolution Medicines says NEJM publishes Phase 1/2 daraxonrasib pancreatic cancer data

Revolution Medicines

Revolution Medicines

RVMD

0.00
  • Revolution Medicines disclosed New England Journal of Medicine publication of Phase 1/2 clinical results for daraxonrasib in previously treated metastatic RAS-mutant pancreatic cancer, with results already presented via the journal report.
  • Study showed encouraging anti-tumor activity with durable responses, supporting a move into late-stage development without detailing technical metrics.
  • Publication underpinned launch of global randomized Phase 3 registrational trial RASolute 302, with topline results already announced as showing an overall survival benefit versus standard chemotherapy.
  • Daraxonrasib also being tested in additional global Phase 3 registrational trials, including earlier-line pancreatic cancer and metastatic RAS-mutant non-small cell lung cancer, widening potential commercial reach beyond single indication.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revolution Medicines Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605061800PRIMZONEFULLFEED9714939) on May 06, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.